ArticleClinical interventions in aging2025
Interpretable Machine Learning Model for Predicting 1-Year Unplanned Readmissions in Ischemic Stroke Patients with Diabetes: A Synergistic View of Inflammation and Metabolism.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of key metabolic indicators associated with the comorbidity of ischemic stroke and diabetes mellitus using an optimal interpretable clinlabomics model.Frontiers in cardiovascular medicine · 2026Article
- Case Report: Ultrasound guided puncture for type 2 diabetes mellitus combined with psoas abscess-a report of two cases.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To develop and validate an interpretable machine learning (ML) model integrating inflammatory and metabolic biomarkers for predicting the risk of 1-year unplanned readmission in patients with ischemic stroke (IS) and type 2 diabetes mellitus (T2DM). Methods: This retrospective study included IS patients with comorbid T2DM who were hospitalized between June 2022 and December 2023. A total of 49 clinical variables were extracted. Least absolute shrinkage and selection operator (LASSO) regression was used for feature selection. The dataset was randomly divided into a training set (70%) and a validation set (30%). Seven widely used ML algorithms were applied to construct predictive models, and model performance was evaluated using a validation set. No external validation was performed in this study. The best-performing model was further interpreted using Shapley Additive Explanations (SHAP), and a dynamic nomogram was developed for individualized risk assessment. Results: A total of 833 patients were included, with a 1-year unplanned readmission rate of 34.3%. LASSO regression identified nine key variables: age, neutrophil-to-lymphocyte ratio (NLR), homocysteine (HCY), glycated hemoglobin A1c (HbA1c), triglyceride-glucose (TyG) index, metformin use, and the presence of hyperlipidemia, pulmonary infection, and renal insufficiency. The random forest model demonstrated the best overall performance (area under the curve [AUC] = 0.78, F1 score = 0.70). SHAP analysis indicated that NLR, HCY, HbA1c, and TyG index were the most influential predictors, suggesting that chronic inflammation and metabolic dysregulation play pivotal roles in readmission risk. Conclusion: The ML model based on inflammatory and metabolic biomarkers effectively predicts 1-year unplanned readmission risk in IS patients with T2DM, with good interpretability and clinical potential. The dynamic nomogram enables real-time, individualized risk prediction to support early identification of high-risk patients, tailored follow-up, and targeted allocation of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.